3,491 Shares in Astrazeneca Plc $AZN Bought by OneAscent Family Office LLC

OneAscent Family Office LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 3,491 shares of the company’s stock, valued at approximately $613,000.

Other hedge funds have also bought and sold shares of the company. Triumph Capital Management bought a new stake in Astrazeneca during the third quarter worth $25,000. Bangor Savings Bank lifted its holdings in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares during the period. Eagle Bay Advisors LLC purchased a new stake in Astrazeneca in the fourth quarter worth $30,000. YANKCOM Partnership purchased a new stake in Astrazeneca in the fourth quarter worth $31,000. Finally, TFC Financial Management Inc. increased its position in Astrazeneca by 3,350.0% in the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after buying an additional 335 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Price Performance

Astrazeneca stock opened at $186.06 on Friday. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The business has a 50-day simple moving average of $190.84 and a 200 day simple moving average of $184.91. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market cap of $288.57 billion, a price-to-earnings ratio of 27.94, a PEG ratio of 1.56 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. On average, research analysts forecast that Astrazeneca Plc will post 9.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on AZN shares. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings started coverage on Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.